# **AMENDMENTS TO THE CLAIMS**

### 1.-48. (Cancelled)

49. (Currently amended) A compound of general formula I

#### wherein

R<sub>1</sub> is halogen, hydroxy, mercapto, trifluoromethyl, amino, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-6</sub>alkylamino, C<sub>1-4</sub>alkoxycarbonyl, cyano, -CONH<sub>2</sub> or nitro;

R<sub>2</sub> is halogen, hydroxy, mercapto, trifluoromethyl, amino, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, C<sub>1-6</sub>alkylamino, C<sub>1-4</sub>alkoxycarbonyl, cyano, -CONH<sub>2</sub>, phenyl or nitro;

R<sub>3</sub> represents fluoro one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, cyano, carboxy, CONH<sub>2</sub>, nitro, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, C<sub>1-4</sub>alkoxycarbonyl; R<sub>4</sub> is fluoro;

wherein R<sub>3</sub> is in the meta position with respect to R<sub>4</sub> and para with respect to -NH;

 $R_a$ ,  $R_b$  and  $R_c$  are the same or different, each representing hydrogen,  $C_{1\text{-4}}$  alkyl,  $C_{2\text{-4}}$  alkenyl,  $C_{2\text{-4}}$  alkynyl,  $C_{3\text{-8}}$  carbocyclyl,  $C_{1\text{-12}}$  heterocyclyl or aryl, each of  $C_{1\text{-4}}$  alkyl,  $C_{2\text{-4}}$  alkynyl,

 $C_{3-8}$ carbocyclyl,  $C_{1-12}$ heterocyclyl or aryl being optionally substituted by one or more, same or different substituents represented by  $R_7$ ;

 $R_7$  is halogen, hydroxy, mercapto, trifluoromethyl, amino,  $C_{1-4}$ alkyl,  $C_{1-6}$ hydroxyalkyl,  $C_{1-4}$ alkoxy,  $C_{1-4}$ alkylthio,  $C_{1-6}$  alkylamino,  $C_{1-4}$ alkoxycarbonyl,  $C_{1-9}$  trialkylammonium in association with an anion, cyano, azido, nitro,  $-S(O)_2NH_2$ ,  $-S(O)_2NR_aR_b$ ,  $-S(O)_2R$ , -COOH,  $-CONH_2$ ,  $-NR_aC(O)R'$ , -CONHR' or -CONRR', wherein R and R' are same or different, each representing hydrogen or  $C_{1-3}$ alkyl;

one of  $R_5$  and  $R_6$  is -COOH, -C(O)NHOH,  $-C(O)NHNH_2$ ,  $Y_2R_9$ ,  $Y_2R_9Y_3R_{10}$ ,  $C_{1-6}$ alkyl- $Y_2R_9$ ,  $C_{1-6}$ alkyl- $Y_2R_9Y_3R_{10}$ ,  $C_{2-6}$ alkenyl- $Y_2R_9$ ,  $C_{2-6}$ alkenyl- $Y_2R_9Y_3R_{10}$ ,  $Y_2R_9-C_{1-6}$ -alkyl- $Y_3R_{10}$ ,  $Y_2R_9-C_{2-6}$ -alkenyl- $Y_3R_{10}$ ,  $C_{3-12}$ carbocyclyl- $Y_2R_9$ ,  $C_{3-12}$ carbocyclyl- $Y_2R_9Y_3R_{10}$ ,  $C_{1-12}$ heterocyclyl- $Y_2R_9Y_3R_{10}$ ,  $C_{3-12}$ carbocyclyl- $C_{1-6}$ -alkyl- $Y_2R_9$ ,  $C_{3-12}$ carbocyclyl- $C_{1-6}$ -alkyl- $Y_2R_9Y_3R_{10}$ ,  $C_{1-12}$ heterocyclyl- $C_{1-6}$ -alkyl- $Y_2R_9Y_3R_{10}$ ,  $C_{3-12}$ carbocyclyl- $C_{1-6}$ -alkyl- $Y_3R_{10}$ ,  $C_{1-12}$ heterocyclyl- $C_{1-6}$ -alkyl- $Y_3R_{10}$ ,  $C_{1-12}$ heterocyclyl- $C_{1-10}$ alkyl,  $C_{3-12}$ carbocyclyl- $C_{1-10}$ alkyl,  $C_{1-10}$ alkyl- $C_{1-10}$ alkyl,  $C_{1-10}$ alkyl- $C_{1-10}$ alkyl,  $C_{2-10}$ alkynyl,  $C_{3-12}$ carbocyclyl or  $C_{1-12}$ heterocyclyl, each of which being optionally substituted by one or more, same or different substituents represented by  $R_7$ , and the other is hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkylthio,  $C_{1-6}$ alkylamino,  $C_{1-4}$ alkoxycarbonyl, cyano, -CONH2 or nitro,

with the proviso that when  $R_5$  or  $R_6$  is phenyl,  $C_{1-5}$ alkyl or  $C_{2-3}$ alkenyl, said  $R_5$  or  $R_6$  is substituted by one or more, same or different substituents represented by  $R_7$  (except three fluorine when  $R_5$  or  $R_6$  is methyl),

with the further proviso that when R<sub>5</sub> or R<sub>6</sub> is COOH, R<sub>3</sub> cannot be nitro,

 $Y_2 \text{ is -O-, -S-, -S(O)-, -S(O)_2-, -NR_a-, -NR_aC(O)NR_b-, -NR_aC(O)-, -C(O)NR_a-, -C(O)NR_aO-, -C(O)-, -NR_aC(O)O-, -NR_aS(O)_2-, -OC(O)-, -C(O)O-, -C(O)NR_aNR_bC(S)NR_c-, -C(O)NR_aNR_b-, or -S(O)_2NR_a-;$ 

 $R_9$  is  $C_{1-10}$ alkyl- $C_{1-12}$ heterocyclyl,  $C_{1-10}$ alkyl- $C_{3-12}$ carbocyclyl,  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-12}$ carbocyclyl,  $C_{1-12}$ heterocyclyl,  $C_{3-12}$ carbocyclyl- $C_{1-10}$ alkyl, or  $C_{1-12}$ heterocyclyl- $C_{1-10}$ alkyl,  $C_{3-6}$ carbocyclyl- $C_{1-6}$ alkenyl,  $C_{3-6}$ carbocyclyl- $C_{2-6}$ alkynyl, each being optionally substituted by one or more, same or different substituents represented by  $R_7$ ,

with the proviso that when  $Y_2$  is  $-O_7$ ,  $-NR_a^2$ ,  $-S_7$  or  $-C(O)O_7$ , and  $R_9$  is  $C_{1-6}$ alkyl, said  $C_{1-6}$ alkyl is substituted by one or more, same or different substituents represented by  $R_7$ ;

 $Y_3$  is -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -NR<sub>a</sub>-, -NR<sub>a</sub>C(O)NR<sub>b</sub>-, -NR<sub>a</sub>C(O)-, -C(O)NR<sub>a</sub>-, -C(O)NR<sub>a</sub>O-, -C(O)-, -NR<sub>a</sub>C(O)O-, -NR<sub>a</sub>S(O)<sub>2</sub>-, -OC(O)- or -C(O)O-;

 $R_{10}$  is  $C_{1-10}$ alkyl- $C_{1-12}$ heterocyclyl,  $C_{1-10}$ alkyl- $C_{3-12}$ carbocyclyl,  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-12}$ carbocyclyl or  $C_{1-12}$ heterocyclyl, each being optionally substituted by one or more, same or different substituents represented by  $R_7$ ;

or, when one of  $R_5$  or  $R_6$  is the group  $-C(O)NR_aR_9$ ,  $R_a$  and  $R_9$  together with the nitrogen atom to which they are attached form a  $C_{1-12}$ heterocyclic ring optionally comprising one or more additional heteroatoms selected from the group consisting of O, S and N, optionally substituted with one or more substituents represented by  $R_7$ ;

or a pharmaceutically acceptable salt, solvate, or ester thereof.

50. (Currently amended) A compound according to claim 49, wherein  $R_1$  is methyl, ethyl, trifluoromethyl, methoxy, ethoxy, nitro, bromo, fluoro or chloro; wherein  $R_2$  is methyl, ethyl,

4 ADM/mao

methoxy, ethoxy, amino, nitro, bromo, fluoro or chloro; and wherein R<sub>3</sub> is hydrogen, methyl, ethyl, methoxy, ethoxy, bromo, fluoro, or chloro.

## 51.-62. (Cancelled)

- 63. (Previously Presented) A compound according to claim 49, wherein R<sub>7</sub> is halogen, hydroxy, amino, -S(O)<sub>2</sub>CH<sub>3</sub>, trifluoromethyl, cyano, C<sub>1-4</sub>hydroxyalkyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylthio, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>alkoxycarbonyl, -COOH, -CONH<sub>2</sub>, -S(O)<sub>2</sub>NH<sub>2</sub>, azido, -CONHR' or -CONRR', wherein R and R' are as indicated in claim 49.
- 64. (Previously presented) A compound according to claim 49, wherein R<sub>7</sub> is methyl, ethyl, methoxy, ethoxy, hydroxy, methoxycarbonyl, ethoxycarbonyl, dimethylamino, ethylamino, amino, -COOH, fluoro, chloro, bromo, -CONH<sub>2</sub>, -S(O)<sub>2</sub>NH<sub>2</sub>, azido, methylthio, -S(O)<sub>2</sub>CH<sub>3</sub>, trifluoromethyl, cyano or hydroxymethyl.
- 65. (Previously Presented) A compound according to claim 49, wherein one of  $R_5$  and  $R_6$  is  $Y_2R_9$ ,  $C_{1-4}$ alkyl- $Y_2R_9$ ,  $Y_2R_9Y_3R_{10}$ ,  $C_{1-4}$ alkyl- $Y_2R_9Y_3R_{10}$ ,  $C_{2-4}$ alkenyl- $Y_2R_9$ ,  $C_{2-4}$ alkenyl- $Y_2R_9$ ,  $Y_2R_9-C_{1-4}$ -alkyl- $Y_3R_{10}$ ,  $Y_2R_9-C_{2-4}$ -alkenyl- $Y_3R_{10}$ ,  $C_{1-6}$ heterocyclyl- $C_{1-4}$ -alkyl- $Y_2R_9$ ,  $C_{1-4}$ alkyl- $C_{1-6}$ heterocyclyl,  $C_{1-4}$ alkyl- $C_{3-6}$ carbocyclyl,  $C_{3-6}$ carbocyclyl,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkyl substituted by  $R_7$ ,  $C_{2-4}$ alkenyl,  $C_{2-4}$  alkynyl,  $C_{3-6}$ carbocyclyl,  $C_{1-6}$ heterocyclyl, -COOH, C(O)NHOH, or  $C(O)NHNH_2$ , and the other is hydrogen, halogen,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy; wherein  $R_9$  is  $C_{1-4}$ alkyl- $C_{1-6}$  heterocyclyl,  $C_{1-4}$ alkyl- $C_{3-6}$ carbocyclyl,  $C_{1-6}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{3-10}$ carbocyclyl,  $C_{1-6}$ heterocyclyl,  $C_{3-6}$ carbocyclyl- $C_{1-6}$ alkyl,  $C_{1-6}$ heterocyclyl- $C_{2-4}$ alkenyl,  $C_{3-6}$ carbocyclyl- $C_{2-4}$ alkynyl; and wherein  $C_{1-6}$  is  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{3-6}$ carbocyclyl- $C_{2-4}$ alkynyl; and wherein  $C_{1-6}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{3-6}$ carbocyclyl- $C_{2-4}$ alkenyl,  $C_{3-6}$ carbocyclyl- $C_{2-4}$ alkenyl,  $C_{3-6}$ carbocyclyl or  $C_{1-6}$ heterocyclyl.
- $66. \ (Previously\ Presented)\ A\ compound\ according\ to\ claim\ 49,\ wherein\ R_5\ is\ Y_2R_9,\ C_{1-4}alkyl-Y_2R_9,\ Y_2R_9Y_3R_{10},\ C_{1-4}alkyl-Y_2R_9Y_3R_{10},\ C_{2-4}alkenyl-Y_2R_9,\ C_{2-4}alkenyl-Y_2R_9Y_3R_{10},\ Y_2R_9-C_{1-4}alkyl-Y_2R_9,\ C_{1-4}alkyl-Y_2R_9,\ C_{1-4}alkyl-Y_2R_9,\ C_{1-4}alkyl-C_{1-4}alkyl-Y_2R_9,\ C_{1-4}alkyl-C_{1-4}$

 $_{6}$ heterocyclyl,  $C_{1-4}$ alkyl- $C_{3-6}$ carbocyclyl,  $C_{3-6}$ carbocyclyl- $C_{1-4}$ alkyl,  $C_{1-4}$ alkyl substituted by  $R_{7}$ ,  $C_{2-4}$ alkenyl,  $C_{2-4}$  alkynyl,  $C_{3-6}$ carbocyclyl,  $C_{1-6}$ heterocyclyl, -COOH, -C(O)NHOH, or C(O)NHNH2, and  $R_{6}$  is hydrogen, halogen,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy; wherein  $R_{9}$  is  $C_{1-4}$ 4heterocyclyl,  $C_{1-6}$ alkyl,  $C_{1-3}$ alkyl- $C_{1-5}$ heterocyclyl,  $C_{6-10}$ carbocyclyl,  $C_{1-3}$ alkyl- $C_{6}$ carbocyclyl,  $C_{3}$ alkenyl,  $C_{6}$ carbocyclyl- $C_{1}$ alkyl,  $C_{6}$ carbocyclyl- $C_{3}$ alkenyl or  $C_{6}$ carbocyclyl- $C_{2}$ alkynyl; and wherein  $R_{10}$  is methyl, ethyl, methacryl, tert-butyl, tetrahydropyranyl or ethenyl.

67. (Previously Presented) A compound according to claim 49, wherein one of  $R_5$  and  $R_6$  is  $Y_2R_9$ ,  $Y_2R_9Y_3R_{10}$ , phenyl, methylphenyl, methyl, propenyl, methyl- $Y_2R_9$ , tetrazole, ethynyl, triazole, thiadiazole, dihydrooxazole,-COOH, -C(O)NHOH, or C(O)NHNH<sub>2</sub>, and the other is hydrogen, fluoro, chloro, methyl or methoxy; wherein  $R_9$  is morpholinyl, propylmorpholinyl, piperazinyl, methyl, ethyl, n-propyl, n-butyl, *tert*-butyl, isobutyl, hexyl, isopropyl, dimethylpropyl, methyltetrahydrofuranyl, methylpyridinyl, ethylpiperazinyl, cyclohexyl, propyloxopyrrolidinyl, benzyl, methylcyclohexyl, propylphenyl, ethylmorpholinyl, allyl, ethylfuranyl, phenyl, methyldioxoimidazolidinyl, dioxohexahydropyrimidinyl, thiazolyl, methylphenyl, ethylphenyl, methyldioxolanyl, methylthiazolyl, propenylphenyl, methylfuranyl, thiophenyl, tetrahydropyranyl or ethynylphenyl; and wherein  $R_{10}$  is methyl, ethyl, methacryl, tetrt-butyl, tetrahydropyranyl or ethenyl.

- 68. (Previously Presented) A compound according to claim 49, wherein R<sub>6</sub> is hydrogen.
- 69. (Previously Presented) A compound according to claim 49, wherein R<sub>5</sub> is hydrogen.
- 70. (Previously Presented) A compound according to claim 49, wherein  $Y_2$  is -O-, -NR<sub>a</sub>-, -NR<sub>a</sub>C(O)NR<sub>b</sub>-, -NR<sub>a</sub>C(O)-, -C(O)NR<sub>a</sub>-, -C(O)NR<sub>a</sub>O-, -C(O)-, -NR<sub>a</sub>C(O)O-, -NR<sub>a</sub>S(O)<sub>2</sub>-, -C(O)NR<sub>a</sub>NR<sub>b</sub>- or -S(O)<sub>2</sub>NR<sub>a</sub>-.
- 71. (Previously Presented) A compound according to claim 49, wherein  $Y_3$  is -O-, -NR<sub>a</sub>C(O)-, -C(O)NR<sub>a</sub>-, -C(O)-, -C(O)O- or -NR<sub>a</sub>C(O)O-.

#### 72.-76. (Cancelled)

77. (Previously Presented) A compound according to claim 49, wherein said heterocycle or heterocyclyl contains one or two oxygen atoms or one sulphur atom, and/or up to two nitrogen atoms, or three or four nitrogen atoms, wherein optionally one or two  $CH_2$  ring fragments is/are replaced by one or two -C(O)- fragments respectively.

78. (Previously Presented) A compound according to claim 49, wherein Ra, Rb, or Rc independently represent hydrogen, methyl, ethyl, 2-hydroxyethyl or 2-methoxyethyl.

79. (Currently amended) A compound according to claim 49, wherein R<sub>1</sub> is methyl, ethyl, methoxy, ethoxy, bromo, fluoro or chloro; and R<sub>2</sub> is methyl, ethyl, methoxy, ethoxy, nitro, bromo, fluoro or chloro; R<sub>3</sub> represents one substituent which is hydrogen, methyl, ethyl, methoxy, ethoxy, bromo, fluoro or chloro, and wherein R<sub>3</sub> is in the meta position with respect to R<sub>4</sub> and para with respect to NH, or wherein R<sub>3</sub> is in the ortho position with respect to R<sub>4</sub> and meta with respect to NH.

- 80. (Currently amended) A compound according to claim 49 selected from the group consisting of
- 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-*N*-(2-hydroxyethyl)-4-methylbenzamide (Compound 115),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-4-methyl-benzamide (Compound 120),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-4,N-dimethyl-benzamide (Compound 121),
- (2-{3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-acetylamino)-acetic acid ethyl ester (Compound 122),

- {3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-acetic acid ethyl-ester (Compound 123),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-N-(2-methoxy-ethyl)-4-methyl-benzamide (Compound 124),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-*N*-cyclohexyl-4-methyl-benzamide (Compound 125),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-*N*-ethyl-4-methyl-benzamide (Compound 126),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-N-(6-hydroxy-hexyl)-4-methyl-benzamide (Compound 127),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-N-isopropyl-4-methyl-benzamide (Compound 128),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-N-isobutyl-4-methyl-benzamide (Compound 129),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-N-(2,2-dimethyl-propyl)-4-methyl-benzamide (Compound 130),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-N-(3-methoxy-propyl)-4-methyl-benzamide (Compound 131),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-4-methyl-*N*-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-benzamide (Compound 132),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-N-(2-dimethylamino-ethyl)-4-methylbenzamide (Compound 133),
- 2-Methyl-acrylic acid 2-{3-[2-chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-ethyl ester (Compound 134),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-N-cis-(4-hydroxy-cyclohexyl)-4-methyl-benzamide (Compound 135),
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-*N*-trans-(4-hydroxy-cyclohexyl)-4-methyl-benzamide (Compound 136),

8 ADM/mao

- (2-{3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-ethyl)-carbamic acid tert-butyl ester (Compound 137),
- N-(2 Amino ethyl) 3-[2 chloro 4-(4-chloro 2-fluoro-phenylamino) benzoyl]-4-methyl-benzamide (Compound 138),
- (2-{3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-acetylamino)-acetic acid (Compound 139),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-4-methoxy-benzamide (compound 140),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,2-difluoro-ethyl)-4-methoxy-benzamide (compound 141),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-fluoro-ethyl)-4-methoxy-benzamide (compound 142),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,3-dihydroxy-propyl)-4-methoxy-benzamide (compound 143),
- *N*-Carbamoylmethyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methoxy-benzamide (compound 144),
- *N*-Carbamoylmethyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (Compound 145),
- N-Benzyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 146),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-fluoro-ethyl)-4-methyl-benzamide (compound 147),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2,2,2-trifluoro-ethyl)-benzamide (compound 148),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-ethyl-4-methyl-benzamide (compound 149),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-cyclohexylmethyl-4-methyl-benzamide (compound 150),

- Docket No.: 3893-0220PUS2
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-propyl)-4-methyl-benzamide (compound 151),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,3-dihydroxy-propyl)-4-methylbenzamide (compound 152),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(1-hydroxymethyl-propyl)-4-methyl-benzamide (compound 153),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2,2,3,3,3-pentafluoro-propyl)-benzamide (compound 154),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(3-hydroxy-propyl)-4-methyl-benzamide (compound 155),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-1,1-dimethyl-ethyl)-4-methyl-benzamide (compound 156),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-1-hydroxymethyl-1-methyl-ethyl)-4-methyl-benzamide (compound 157),
- {3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-acetic acid ethyl ester (compound 158),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(4-hydroxy-butyl)-4-methyl-benzamide (compound 159),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(3-hydroxy-1,1-dimethyl-butyl)-4-methyl-benzamide (compound 160),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(3-phenyl-propyl)-benzamide (compound 161),
- (R)-3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(1-hydroxymethyl-3-methyl-butyl)-4-methyl-benzamide (compound 162),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-isopropyl-4-methyl-benzamide (compound 164),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-cyclohexyl-4-methyl-benzamide (compound 165),

- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,2-difluoro-ethyl)-4-methyl-benzamide (compound 166),
- 5-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-4-oxopentanoic acid methyl ester (compound 167),
- *N*-[(2-Carbamoyl-ethylcarbamoyl)-methyl]-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 168),
- (2-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-acetylamino)-acetic acid ethyl ester (compound 169),
- N-Allyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 170),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2-sulfamoyl-ethyl)-benzamide (compound 171),
- *N*-(2-Acetylamino-ethyl)-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methylbenzamide (compound 172),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-N (2-hydroxy-ethyl)-4-methoxy-benzamide (compound 173),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino) benzoyl] N (2-fluoro-ethyl)-4-methoxy-benzamide (compound 174),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-*N*-(2,3-dihydroxy-propyl)-4-methoxy-benzamide (compound 175),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-*N*-(3-hydroxy-propyl)-4-methoxy-benzamide (compound 176),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-4-methoxy-N-phenethyl-benzamide (compound 177),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-N-(2-hydroxy-1,1-dimethyl-ethyl)-4-methoxy-benzamide (compound 178);
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino) benzoyl]-4-methoxy-N-(2-morpholin-4-yl-ethyl)-benzamide (compound 179),

- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-N-(2-hydroxy-1-hydroxymethyl-1-methyl-ethyl)-4-methoxy-benzamide (compound 180),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-4-methoxy-*N*-methyl-benzamide (compound 181),
- {3-[2-Chloro-4-(2,6-difluoro-phenylamino) benzoyl] 4-methoxy-benzoylamino}-acetic acid ethyl ester (compound 182),
- (2-{3-[2-Chloro-4 (2,6-difluoro-phenylamino)-benzoyl]-4-methoxy-benzoylamino}-acetylamino)-acetic acid ethyl ester (compound 183),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl] *N,N*-bis-(2-hydroxy-ethyl)-4-methoxy-benzamide (compound 184),
- 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-4-methoxy-N,N-bis-(2-methoxy-ethyl)-benzamide (compound 185),
- 4-Chloro-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-benzamide (compound 204),
- *N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-methoxy-propionamide (compound 241),
- *N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-propionamide (compound 242),
- *N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-2-(2-methoxy-ethoxy)-acetamide (compound 243),
- *N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-morpholin-4-yl-propionamide (compound 244),
- *N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-hydroxy-propionamide (compound 245),
- *N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-furan-2-yl-propionamide (compound 246),
- *N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-2-hydroxy-benzamide (compound 247),

*N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-2-(2,5-dioxo-imidazolidin-4-yl)-acetamide (compound 248),

2,6-Dioxo-hexahydro-pyrimidine-4-carboxylic acid {3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-amide (compound 249),

Acrylic acid 2-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenylcarbamoyl}-ethyl ester (compound 250),

*N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-methylsulfanyl-propionamide (compound 251),

*N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-methanesulfonyl-propionamide (compound 252),

Ethanesulfonic acid {3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-amide (compound 253),

*N*-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-4-methoxy-benzenesulfonamide (compound 254),

*N*-(5-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenylsulfamoyl}-4-methyl-thiazol-2-yl)-acetamide (compound 255),

5-Acetyl-2-chloro-*N*-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-benzenesulfonamide (compound 256),

Naphthalene-2-sulfonic acid {3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methylphenyl}-amide (compound 257),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-C-phenyl-methanesulfonamide (compound 258),

2-Methyl-acrylic acid 2-(3-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-ureido)-ethyl ester (compound 259),

1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(2-hydroxy-ethyl)-urea (compound 260),

(3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-ureido)-acetic acid ethyl ester (compound 261),

- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(3-methoxy-phenyl)-urea (compound 262),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(3-trifluoromethyl-phenyl)-urea (compound 263),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-propyl-urea (compound 264),
- 3-(3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-ureido)-propionic acid ethyl ester (compound 265),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-cyclohexyl-urea (compound 266),
- 1-Allyl-3-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-urea (compound 267),
- 1-Benzyl-3-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-urea (compound 268),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-ethyl-urea (compound 269),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-phenyl-urea (compound 270),
- 1-Butyl-3-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-urea (compound 271),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-phenethyl-urea (compound 272),
- 2-(3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-ureido)-benzoic acid methyl ester (compound 273),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(3-cyano-phenyl)-urea (compound 274),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-isopropyl-urea (compound 275),

- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(4-methoxy-phenyl)-urea (compound 276),
- {3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-carbamic acid benzyl ester (compound 277),
- {3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-carbamic acid allyl ester (compound 278),
- {3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-carbamic acid ethyl ester (compound 279),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(3-hydroxy-butylamino)-2-methyl-phenyl]-methanone (compound 281),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(3'-hydroxymethyl-4-methyl-biphenyl-3-yl)-methanone (compound 282),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(3'-hydroxy-4-methyl-biphenyl-3-yl)-methanone (compound 283),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(4'-methoxy-4-methyl-biphenyl-3-yl)-methanone (compound 284),
- *N*-{3'-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4'-methyl-biphenyl-3-yl}-acetamide (compound 285),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(4-methyl-3'-trifluoromethoxy-biphenyl-3-yl)-methanone (compound 286),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(3',4',5'-trifluoro-4-methyl-biphenyl-3-yl)-methanone (compound 288),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(3',4'-dimethoxy-4-methyl-biphenyl-3-yl)-methanone (289),
- 3'-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4'-methyl-biphenyl-3-carbonitrile (compound 290),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-4-methyl-benzenesulfonamide (compound 291),

- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2-morpholin-4-yl-ethyl)-benzenesulfonamide (compound 292),
- *N*-Allyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzenesulfonamide (compound 293),
- *N*-(2-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzenesulfonylamino}-ethyl)-acetamide (compound 294),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-propyl-benzenesulfonamide (compound 295),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,3-dihydroxy-propyl)-4-methylbenzenesulfonamide (compound 296),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-methoxy-ethyl)-4-methyl-benzenesulfonamide (compound 297),
- [4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[5-(4-methoxy-benzyloxy)-2-methyl-phenyl]-methanone (Compound 306),
- [4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[5-(3-hydroxy-propoxy)-2-methyl-phenyl]-methanone (Compound 307),
- [2-Amino-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(3-hydroxy-propoxy)-2-methyl-phenyl]-methanone (compound 308),
- [4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[2-methyl-5-(2-morpholin-4-yl-ethoxy)-phenyl]-methanone (compound 309),
- [2-Amino-4-(2,4-difluoro-phenylamino)-phenyl]-[2-methyl-5-(2-morpholin-4-yl-ethoxy)-phenyl]-methanone (compound 310),
- [4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[5-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-methyl-phenyl]-methanone (compound 311),
- [4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[5-(2,3-dihydroxy-propoxy)-2-methyl-phenyl]-methanone (compound 312),
- [2-Amino-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(2,3-dihydroxy-propoxy)-2-methyl-phenyl]-methanone (compound 313),

- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[2-fluoro-5-(3-hydroxy-propoxy)-phenyl]-methanone (compound 314),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-fluoro-phenyl]-methanone (compound 315),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(2,3-dihydroxy-propoxy)-2-fluoro-phenyl]-methanone (Compound 316),
- [2-Chloro-4-(2,6-difluoro-phenylamino)-phenyl]-[2-chloro-5-(2-morpholin-4-yl-ethoxy)-phenyl]-methanone (compound 328),
- (±)-[2-Chloro-4-(2,6-difluoro-phenylamino)-phenyl]-[2-chloro-5-(2,3-dihydroxy-propoxy)-phenyl]-methanone (compound 329),
- [5-(3-Bromo-propoxy)-2-chloro-phenyl]-[2-chloro-4-(2,6-difluoro-phenylamino)-phenyl]-methanone (compound 330),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(5-hydroxymethyl-2-methyl-phenyl)-methanone (compound 331),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(5-chloromethyl-2-methyl-phenyl)-methanone (compound 332),
- (5-Azidomethyl-2-methyl-phenyl)-[2-chloro-4-(2,4-difluoro-phenylamino)-phenyl]-methanone (compound 333),
- (5-Aminomethyl-2-methyl-phenyl)-[2-chloro-4-(2,4-difluoro-phenylamino)-phenyl]-methanone (compound 334),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(5-hydroxymethyl-2-methoxy-phenyl)-methanone (compound 335),
- Acetic acid 3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methoxy-benzyl ester (compound 336),
- *N-tert*-Butoxy-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methoxy-benzamide (compound 337),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-methoxy-4-methyl-benzamide (compound 338),

- N-Butoxy-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 339),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-cyclohexylmethoxy-4-methyl-benzamide (compound 340),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2-methyl-thiazol-4-ylmethoxy)-benzamide (compound 341),
- N-benzyloxy-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 342),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(4-methoxy-benzyloxy)-4-methylbenzamide (compound 343),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoic acid *N'*,*N'*-dimethyl-hydrazide (compound 344),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-morpholin-4-yl-benzamide (compound 345),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-hydroxy-4-methyl-benzamide (compound 346),
- 4-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-3-methyl-benzamide (compound 347),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(3-hydroxy-propenyl)-2-methyl-phenyl]-methanone (compound 348),
- 4-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-thiophene-3-carboxylic acid methyl ester (compound 349),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-furan-2-ylmethyl-4-methyl-benzamide (compound 350),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(3-methoxy-phenyl)-4-methyl-benzamide (compound 351),
- 2-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-benzoic acid methyl ester (compound 352),

- 3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-thiophene-2-carboxylic acid methyl ester (compound 353),
- 4-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-thiophene-3-carboxylic acid (compound 354),
- 2-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-benzoic acid (compound 355),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-[2-(2-hydroxy-ethylcarbamoyl)-phenyl]-4-methyl-benzamide (compound 356),
- 3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-thiophene-2-carboxylic acid (2-hydroxy-ethyl)-amide (compound 357),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(5-ethynyl-2-methyl-phenyl)-methanone (compound 362),
- 3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoic acid hydrazide (compound 364),
- 1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoyl}-4-ethyl-3-thio semicarbazide (compound 365),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(5-ethylamino-[1,3,4]thiadiazol-2-yl)-2-methyl-phenyl]-methanone (compound 366),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[2-methyl-5-(1H-tetrazol-5-yl)-phenyl]-methanone (compound 367),
- 3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-oxo-propionic acid ethyl ester (compound 368),
- [2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(4,5-dihydro-oxazol-2-yl)-2-methyl-phenyl]-methanone (compound 369),
- 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoic acid (Compound 424),
- 2-Methylacrylic acid 2-{3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino}ethyl ester (Compound 425)
- 3-[2-Chloro-4-(4-chloro-2-fluoro-phenylamino)-benzoyl]-4-methyl-benzoic acid (Compound 432).

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methoxy-benzoic acid (compound 437), 3-[2-Chloro-4-(2,6-difluoro-phenylamino)-benzoyl]-4-methoxy-benzoic acid (compound 443),

81. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 49 or a pharmaceutically acceptable salt or ester thereof together with a pharmaceutically acceptable vehicle or excipient.

### 82. (Cancelled)

83. (Withdrawn) A method of preventing, treating or ameliorating inflammatory diseases or conditions, or ophthalmic diseases or conditions, the method comprising administering to a patient in need thereof an effective amount of a compound according to claim 49, wherein the inflammatory or ophthalmic disease or condition is selected from the group consisting of asthma, allergy, arthritis, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, Crohn's disease, neurological inflammations, inflammatory eye diseases, proliferative and inflammatory skin disorders, psoriasis, atopic dermatitis, acne, uveitis, sepsis, septic shock or acne, and osteoporosis.

## 84.-87. (Cancelled)

88. (Withdrawn) A method for producing a compound of general structure I,

$$\begin{array}{c|c}
R_5 & R_1 & R_3 \\
R_6 & R_1 & R_4
\end{array}$$

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are defined as in claim 49, comprising the steps of a) transforming a compound general structure VI,

wherein Hal is a halogen, and  $R_1$ ,  $R_5$  and  $R_6$  are defined as in claim 49, each of which are independently protected or unprotected, into an organometallic intermediate;

- b) transmetalating said organometallic intermediate to an organozinc intermediate;
- c) coupling said organozinc intermediate with an acid halide of general structure V,

wherein  $R_2$  is defined as in claim 49, protected or unprotected, in the presence of a catalyst to give a compound of general structure IV,

$$\begin{array}{c|c} R_{5} & R_{1} & NO_{2} \\ \hline \\ R_{6} & IV \end{array}$$

wherein  $R_1$ ,  $R_2$ ,  $R_5$ , and  $R_6$  are defined as above, each of which are independently protected or unprotected;

d) optionally transforming, protecting or deprotecting one or more substituents or functional groups of  $R_1$ ,  $R_2$ ,  $R_5$ , and  $R_6$  of the compound of general structure IV to give another compound of general structure IV;

e) reducing the compound of general structure IV from step c) or d) to an amine of general structure III,

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub>, and R<sub>6</sub> are defined as above, each of which are independently protected or unprotected;

f) optionally transforming, protecting or deprotecting one or more substituents or functional groups of  $R_1$ ,  $R_2$ ,  $R_5$ , and  $R_6$  of the compound of general structure III to give another compound of general structure III;

g) coupling of the amine of general structure III from step e) or f) with a compound of general structure II,

$$R_3$$

wherein L is triflate or halogen, R<sub>3</sub> and R<sub>4</sub> are defined in claim 49, each of which are independently protected or unprotected, to give a compound of general structure I, wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are defined as above, each of which are independently protected or unprotected;

h) optionally transforming, protecting or deprotecting one or more substituents or functional groups of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ , or  $R_6$  of the compound of general structure I from step g) to give a another compound of general structure I.

89. (Withdrawn) A method for producing a compound of general structure I,

22 ADM/mao

$$R_{5}$$
 $R_{6}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 

wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ , and  $R_6$  are defined as in claim 49, comprising the steps of a) transforming a compound general structure VIIa,

wherein Hal is halogen, W is halogen or triflate, and R<sub>2</sub> is as defined in claim 49, protected or unprotected, into an organometallic intermediate;

- b) transmetalating said organometallic intermediate to an organozinc intermediate;
- c) coupling said organozinc intermediate with an acid halide of general structure VIII,

wherein  $R_{1}$ ,  $R_{5}$ , and  $R_{6}$  are as defined in claim 49, each of which are independently protected or unprotected, in the presence of a catalyst to give a compound of general structure IIIa,

23 ADM/mao

$$R_{5}$$
 $R_{6}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{2}$ 
 $R_{3}$ 

wherein W, R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub>, and R<sub>6</sub> are defined as above, each of which are independently protected or unprotected;

- d) optionally transforming, protecting or deprotecting one or more substituents or functional groups of W, R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub>, and R<sub>6</sub> of the compound of general structure IIIa to give another compound of general structure IIIa;
- e) coupling of the compound of general structure IIIa from step c) or d) with an amine of general structure IIa,

$$H_2N$$
 $R_4$ 
 $R_4$ 
 $R_4$ 

wherein R<sub>3</sub> and R<sub>4</sub> are defined as in claim 49, each of which are independently protected or unprotected, to give a compound of general structure I,

wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ , and  $R_6$  are defined as above, each of which are independently protected or unprotected;

f) optionally transforming, protecting or deprotecting one or more substituents or functional groups of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ , or  $R_6$  of the compound of general structure I from step e) to give another compound of general structure I.

# 90. (Cancelled)

Application No. 10/563,474

91. (Previously Presented) A composition according to claim 81 further comprising another active component selected from the group consisting of glucocorticoids, vitamin D analogues, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergenic agents, methyl xanthines, β-adregenic agents, COX-2 inhibitors, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, peniciliamine, serum cholesterol reducing agents, retinoids, zinc salts and salicylazosulfapyridin.

92. (Withdrawn) A method of preventing, treating or ameliorating acute macular degeneration or age-related macular degeneration, the method comprising administering to a patient in need thereof an effective amount of a compound according to claim 49.

25